

RECEIVED
CENTRAL FAX CENTER

SEP 17 2004 11:54

P.01

Fax

SEP 17 2004

Lilly

Eli Lilly and Company
Lilly Corporate Centre
Indianapolis, Indiana 46285
U.S.A.

Date: 17 September 2004

To: Examiner Delacroix-Muirheid
Company: USPTO
Fax: 703-872-9306
Technology Center 1600

From: Greg Cox
Fax: 317-276-5172
Phone: 317-277-2620

Privileged and Confidential Communication**Total Pages: 8**

Subject: GLP-1 Formulations; 10/072,540
Our Reference: X11368A

CONFIDENTIALITY NOTICE: This fax message from Eli Lilly and Company (including all attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply fax and destroy all copies of the original message.

Please contact Jan Fowler at 317-655-1715 if you incur any difficulties with this transmission.

Answers That Matter.

RECEIVED
CENTRAL FAX CENTER

SEP 17 2004

CERTIFICATION OF FACSIMILE TRANSMISSION	
I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.	
Janet Fowler Type or print name of person signing certification	
Signature	Date
<i>Janet Fowler</i>	9/17/04

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	James Arthur Hoffmann)	
Serial No.	:	10/072,540)	
Filed	:	February 8, 2002)	Group Art Unit:
)	1614
For	:	GLP-1 Formulations)	Examiner:
Docket No.	:	X-11368A)	Delacroix-Muirheid

Response and Amendment Under 37 C.F.R. §1.111 and 37 C.F.R. §1.121

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Introductory Comments

This paper is filed in response to the Examiner's rejection of Claims 35-53. Amendments to claims 39, 44, and 53 have been made. New claim 54 has been added. Applicants respectfully request that the Examiner enter the following amendments that Applicants believe place the application in condition for allowance. Amendments to the Claims begin on page 2 of this paper. Remarks and Arguments begin on page 6 of this paper.